NEW YORK (GenomeWeb News) – RNAi research services company Definiens said today that Cenix BioScience has expanded a license agreement to continue to use Definiens’ data extraction technology in its microscopy assays for high throughput RNAi studies in human and rodent cells.
Under the agreement, Cenix will integrate the Definiens Cellenger system into its existing high-throughput and high-content RNAi-based research infrastructure, the company said.